Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Below 200 Day Moving Average – Time to Sell?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) shares crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $2.36 and traded as low as $2.36. Oramed Pharmaceuticals shares last traded at $2.37, with a volume of 43,141 shares.

Wall Street Analyst Weigh In

Separately, StockNews.com cut shares of Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, February 19th.

Oramed Pharmaceuticals Price Performance

The company’s 50-day moving average is $2.30 and its two-hundred day moving average is $2.36. The firm has a market cap of $94.73 million, a P/E ratio of 21.36 and a beta of 1.61.

Institutional Investors Weigh In On Oramed Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. World Equity Group Inc. bought a new position in shares of Oramed Pharmaceuticals in the fourth quarter worth about $48,000. XTX Topco Ltd lifted its holdings in shares of Oramed Pharmaceuticals by 59.7% in the third quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 9,242 shares during the last quarter. Marquette Asset Management LLC bought a new position in shares of Oramed Pharmaceuticals in the fourth quarter worth about $81,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Oramed Pharmaceuticals in the third quarter worth about $272,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Oramed Pharmaceuticals by 143.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company’s stock worth $288,000 after acquiring an additional 70,190 shares during the last quarter. Institutional investors own 12.73% of the company’s stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.